Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Lapatinib (Primary)
- Indications Anaplastic astrocytoma; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Pharmacodynamics; Pharmacokinetics
- 02 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Jun 2019 Planned primary completion date changed from 3 Jun 2019 to 31 Dec 2019.
- 08 Feb 2019 Planned primary completion date changed from 3 Mar 2019 to 3 Jun 2019.